KEROS THERAPEUTICS, INC. (KROS)

11.03 -1.78% (-0.20)

Over 5Y: -67.1%

2026-08-28
20 40 60
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '25 — Revenue: 14.3M Q3 '25 — Operating Cash Flow: 3.2M Q3 '25 — Free Cash Flow: 3.1M Q3 '25 — Net Income: -7.3M Q4 '25 — Revenue: 385K Q4 '25 — Operating Cash Flow: -27.3M Q4 '25 — Free Cash Flow: -27.4M Q4 '25 — Net Income: -23.5M Q1 '26 — Revenue: 367K Q1 '26 — Operating Cash Flow: -3.5M Q1 '26 — Free Cash Flow: -3.6M Q1 '26 — Net Income: -23.7M Q2 '26 — Revenue: 0 Q2 '26 — Operating Cash Flow: -20.4M Q2 '26 — Free Cash Flow: -20.6M Q2 '26 — Net Income: -28.7M -27M -18M -9M 0 9M 18M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 152.3%
OE margin -475.2%
Oper. margin -675.8%
ROIC -1700.5%
Accruals -12.2%
Asset turnover 0.052×
EBITDA margin -665.2%
FCF margin -322.9%
OCF margin -319.7%
Profit margin -553.9%
ROA -28.9%
ROCE -36.8%
ROE -31.7%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.1
RPO / sales 0.01×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

8.5
Current ratio 22.2×
ND/EBITDA —
Cash runway 5.3 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 22.0×
F-score 6.4 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.5
Sales CAGR 4Y +86.7%
Sales/sh Y/Y -93.6%
EPS Y/Y -538.0%
Sales Q/Q -100.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS next Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.